Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Heterogeneity among Epstein-Barr virus-seropositive donors in the generation of immunoblastic B-cell lymphomas in SCID mice receiving human peripheral blood leukocyte grafts

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Picchio, G. R.
  • Kobayashi, R.
  • Kirven, M.
  • Baird, S. M.
  • Kipps, T. J.
  • Mosier, Donald

publication date

  • May 1992

journal

  • Cancer Research  Journal

abstract

  • Epstein-Barr virus (EBV) is associated with B-cell malignancy in immunosuppressed humans and SCID mice receiving human peripheral blood leukocyte grafts (hu-PBL-SCID). We have further characterized the process of lymphoma development in hu-PBL-SCID mice. We report that EBV-seropositive donors differ markedly in the capacity of their PBL to give rise to immunoblastic lymphomas in SCID mice; some donors (high incidence) generated tumors rapidly in all hu-PBL-SCID mice, other donors (intermediate-low incidence) gave rise to sporadic tumors after a longer latent period (greater than 10 weeks), and some donors failed to produce tumors. B-cell lymphomas arising from high incidence donors were multiclonal in origin, and EBV replication was detected in all tumors. Tumors derived from intermediate-low incidence donors were monoclonal or oligoclonal and often had no evidence of viral replication. All tumors, regardless of the donor, resembled EBV-transformed lymphoblastoid cell lines in surface phenotype but differed from lymphoblastoid cell lines by having less Epstein-Barr nuclear antigen 2 and CD23 expression. The variable patterns of lymphomagenesis seen among different EBV-sero-positive donors may be explained by lower levels of specific immunity to EBV in high incidence donors, permitting activation of EBV replication and potential transformation of secondary B-cell targets. In addition, there may be differences in the transforming potential of EBV infecting different donors. The use of the hu-PBL-SCID model may help predict patients at high risk for posttransplant or acquired immunodeficiency syndrome-associated lymphomas.

subject areas

  • Age Factors
  • Animals
  • DNA Replication
  • Herpesvirus 4, Human
  • Humans
  • Incidence
  • Leukocyte Transfusion
  • Leukocytes
  • Lymphoma, B-Cell
  • Mice
  • Mice, SCID
  • Phenotype
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Virus Replication
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0008-5472

PubMed ID

  • 1314693
scroll to property group menus

Additional Document Info

start page

  • 2468

end page

  • 2477

volume

  • 52

issue

  • 9

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support